HIPRA

Last updated

HIPRA is a biotech pharmaceutical company headquartered in Amer, Catalonia, Spain focused on prevention for animal and human health, with a product base of vaccines and diagnostic services. [1]

Contents

HIPRA has an international presence in 40 countries with its own subsidiaries, 3 R&D centres and production plants located in Europe (Spain) and America (Brazil). [2]

In addition, its international distribution network maintains open distribution channels with more than 100 countries, covering all 5 continents. [3]

Since 2020, the company has been developing a vaccine against COVID-19. [4]

History

HIPRA got founded in 1971, in a small laboratory in Madrid. [5] The name HIPRA comes from the surnames of its former creators: Hidalgo and Prada.

In 1991 HIPRA had a workforce of 100 people and a turnover of 10 million euros, it was an important year in HIPRA's history, with a new management team, and a redefined company expansion policy. [2]

In the year 2000, the company began internationalization, beginning the implementation of its own subsidiaries around the world. [5] Currently HIPRA has commercial subsidiaries in 40 countries. It also has 3 research centers and 6 production plants located in Europe and America. [2]

In 2009 HIPRA began to focus on prevention; therefore, it stopped investing in pharmacological products. [5]

In 2021 the new Human Health division was created by HIPRA to create new products. [6] The same year, GoodGut was acquired by HIPRA, a biotechnological start-up dedicated to the research and development of diagnostic tests for digestive diseases. [7]

Animal health

HIPRA has developed more than 100 vaccines for different animal species, both production and companion animals, against a wide variety of biological targets. In addition to its Amer plant, the company has another plant in Brazil, in the Porto Alegre conurbation. It also has a university research centre in the United States. [8]

HIPRA's animal health products include vaccines, vaccination devices, [9] integrated traceability services and diagnostic kits.

Related Research Articles

<span class="mw-page-title-main">Salvador Illa</span> Spanish politician (born 1966)

Salvador Illa Roca is a Spanish politician who served as Minister of Health of Spain from 2020 to 2021. He has been the Secretary for Organization of the Socialists' Party of Catalonia since 2016, and the candidate for the presidency of Catalonia for this party. Previously, Illa served as Mayor of La Roca del Vallès from 1995 to 2005.

The COVID-19 pandemic in Mexico is part of the ongoing worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2.

<span class="mw-page-title-main">COVID-19 pandemic in Panama</span> Ongoing COVID-19 viral pandemic in Panama

The COVID-19 pandemic in Panama was a part of the worldwide pandemic of the coronavirus disease caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Panama on 9 March 2020. One of the dead was a 64-year-old male, who also had diabetes and pneumonia. Of those infected, 83 were hospitalized. The infected individuals belonged to the 29-59 age group and had each recently travelled abroad. A 13-year-old girl died of COVID-19 on 23 March 2020.

The COVID-19 pandemic in Uruguay has resulted in 1,037,893 confirmed cases of COVID-19 and 7,625 deaths.

<span class="mw-page-title-main">CoronaVac</span> Vaccine against COVID-19

CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen, and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), the temperatures at which flu vaccines are kept.

<span class="mw-page-title-main">Pfizer–BioNTech COVID-19 vaccine</span> Type of vaccine for humans

The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in humans to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) that encodes a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial guidance recommended a two-dose regimen, given 21 days apart; this interval was subsequently extended to up to 42 days in the United States, and up to four months in Canada.

<span class="mw-page-title-main">COVID-19 vaccination in Italy</span> Immunization plan against COVID-19 in Italy

The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.

Events in the year 2021 in Uruguay.

<span class="mw-page-title-main">Soberana 02</span> Vaccine against COVID-19

Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. The vaccine is known as PastoCovac in Iran, where it has been developed in collaboration with the Pasteur Institute of Iran.

<span class="mw-page-title-main">COVID-19 vaccination in Peru</span> Plan to immunize against COVID-19

The COVID-19 vaccination program in Peru is the national vaccination strategy to protect the population against SARS-CoV-2 employing vaccines developed for the COVID-19 pandemic in Peru. Vaccination began on 9 February 2021, after three days of arrival of first vaccines. On a nation message, the head of state Francisco Sagasti confirmed the purchase of 38 millions of vaccines, being one million of vaccines for health personnel.

The Argentine COVID-19 vaccination scandal, known in Argentina as vacunatorio VIP, is a political scandal related to the application of COVID-19 vaccines in the Ministry of Health of Argentina to citizens who, due to the limitations established in the vaccination protocol, were not authorized to receive these vaccines yet.

<span class="mw-page-title-main">COVID-19 vaccination in the United States</span> Plan to immunize against COVID-19

The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States. The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, and mass vaccinations began four days later. The Moderna vaccine was granted emergency use authorization on December 17, 2020, and the Janssen vaccine was granted emergency use authorization on February 27, 2021. By April 19, 2021, all U.S. states had opened vaccine eligibility to residents aged 16 and over. On May 10, 2021, the FDA approved the Pfizer-BioNTech vaccine for adolescents aged 12 to 15. On August 23, 2021, the FDA granted full approval to the Pfizer–BioNTech vaccine for individuals aged 16 and over.

The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.

<span class="mw-page-title-main">Vacunagate</span> Political scandal in Peru and Argentina

Vacunagate refers to a scandal in Peru over the secret COVID-19 vaccination of 487 people, mainly senior officials of the Executive Power of Peru. The crisis began on February 10, 2021, with the revelation that in October 2020 a coronavirus vaccine intended for Phase III of the Sinopharm clinical trials was secretly given to then-President Martín Vizcarra.

<span class="mw-page-title-main">COVID-19 vaccination in Mexico</span> Plan to immunize against COVID-19

COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

<span class="mw-page-title-main">COVID-19 vaccination in Indonesia</span> Plan to immunize against COVID-19

The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.

The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.

<span class="mw-page-title-main">COVID-19 vaccination in Spain</span> Immunization plan against COVID-19 in Spain

The COVID-19 vaccination in Spain is the national vaccination strategy started on 27 December 2020 in order to vaccinate the country's population against COVID-19 within the international effort to fight the COVID-19 pandemic.

References

  1. ↑ https://www.hipra.com/en/discover-hipra Retrieved 2024-01-08
  2. 1 2 3 https://www.hipra.com/en/history Retrieved 2024-01-08
  3. ↑ "Hipra". Parc Científic de Barcelona. 2020-10-20. Retrieved 2022-11-14.
  4. ↑ Limón, Raúl (2021-08-12). "First Spanish Covid-19 vaccine approved for human clinical trial". EL PAÍS English Edition. Retrieved 2021-11-05.
  5. 1 2 3 "La vacuna de Hipra crea más anticuerpos que la de Pfizer como dosis de refuerzo". La Vanguardia (in Spanish). 2022-03-15. Retrieved 2022-11-15.
  6. ↑ rumiNews (2020-12-14). "HIPRA da un paso firme hacia la salud humana con la vacuna frente a la Covid-19". Rumiantes el portal de rumiNews. Retrieved 2022-11-15.
  7. ↑ Bosch, Imma. "Hipra compra l'empresa Goodgut - 19 ago 2021". El Punt Avui (in Catalan). Retrieved 2022-11-15.
  8. ↑ "La vacuna de Hipra crea más anticuerpos que la de Pfizer como dosis de refuerzo". La Vanguardia (in Spanish). 2022-03-15. Retrieved 2022-11-18.
  9. ↑ Beek, Vincent ter (2016-06-24). "Hipra takes one step forward in Smart Vaccination". Pig Progress. Retrieved 2022-11-18.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.